Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q3 2024 · 10-Q
Revenue$191.21M$191.21M+5.9% vs Q3 2023 Net Income$40.43M$40.43M−17.9% vs Q3 2023 EPS Diluted$0.78$0.78−14.3% vs Q3 2023 Gross Profit$101,941,000−6.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$59,962,000−6.8% Free Cash Flowderived$46,169,000−14.7% Margins · derivedGross margin53.3%−6.7 pt vs Q3 2023
Operating margin29.8%−10.4 pt vs Q3 2023
Net margin21.1%−6.1 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 7, 2024 · 38 d after period end